Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
暂无分享,去创建一个
C. Escriu | A. Addeo | J. Cave | A. Cortellini | D. Pinato | C. Comins | H. Bainbridge | A. Signori | C. Ottensmeier | F. Gomes | G. Banna | Samuel Chan | S. Muthuramalingam | O. Cantale | H. McKenzie | G. Barone | Alexander Hicks | A. Hicks | S. Chan
[1] Jennifer D. Brooks,et al. Platelet Count and Survival after Cancer , 2022, Cancers.
[2] P. Sorger,et al. Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors , 2022, Clinical Cancer Research.
[3] M. Hellmann,et al. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. H. Kim,et al. A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression , 2021, Journal of clinical medicine.
[5] F. Cappuzzo,et al. Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy , 2021, Thoracic cancer.
[6] H. Nechushtan,et al. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50. , 2021, Clinical lung cancer.
[7] Mingfeng He,et al. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis , 2021, Cancer Immunology, Immunotherapy.
[8] M. Kriegsmann,et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer , 2021, ESMO open.
[9] R. Zhou,et al. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. , 2021, Immunotherapy.
[10] R. Pazdur,et al. Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. , 2021 .
[11] C. Sternberg,et al. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort , 2021, ESMO open.
[12] C. Porta,et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) , 2021, Therapeutic advances in medical oncology.
[13] L. Paz-Ares,et al. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis , 2021, Journal of clinical medicine.
[14] M. Filetti,et al. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer , 2021, ESMO open.
[15] G. Yancopoulos,et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.
[16] S. Gettinger,et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Keunchil Park,et al. Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] A. Agbarya,et al. First line Immunotherapy for Non-Small Cell Lung Cancer , 2020, Pharmaceuticals.
[19] M. Filetti,et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation , 2020, Journal for ImmunoTherapy of Cancer.
[20] G. Giaccone,et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.
[21] E. Feuer,et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. , 2020, The New England journal of medicine.
[22] D. Galetta,et al. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab , 2020, Translational lung cancer research.
[23] C. Bai,et al. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis , 2020, Frontiers in Oncology.
[24] A. Addeo,et al. Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm , 2020, Oncology reviews.
[25] A. Tafreshi,et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] Gengyun Sun,et al. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. , 2020, International immunopharmacology.
[27] Fen Liu,et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors , 2020, Cancer Immunology, Immunotherapy.
[28] S. Novello,et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Marchetti,et al. Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer , 2020, Lung cancer management.
[30] Y. Hosomi,et al. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases , 2019, Journal of Cancer Research and Clinical Oncology.
[31] C. Oldmeadow,et al. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). , 2019, Translational lung cancer research.
[32] G. Che,et al. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. , 2019, Annals of translational medicine.
[33] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[34] A. Addeo,et al. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis , 2019, Front. Oncol..
[35] L. Crinò,et al. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab , 2019, Clinical Cancer Research.
[36] K. Kerr,et al. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC , 2019, Nature Reviews Clinical Oncology.
[37] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] A. Addeo,et al. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. , 2018, Critical reviews in oncology/hematology.
[39] P. Postmus,et al. Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. , 2018, Future oncology.
[40] E. Felip,et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.
[41] Kyung-Hee Kim,et al. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. , 2017, Human pathology.
[42] Lu Shi,et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.
[43] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[44] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[45] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[46] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.